Success Metrics

Clinical Success Rate
100.0%

Based on 18 completed trials

Completion Rate
100%(18/18)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
6%
Ph phase_1
17
94%

Phase Distribution

17

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution18 total trials
Phase 1Safety & dosage
17(94.4%)
Phase 2Efficacy & side effects
1(5.6%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

18 of 18 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

18

all time

Status Distribution
Completed(18)

Detailed Status

Completed18

Development Timeline

Analytics

Development Status

Total Trials
18
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 117 (94.4%)
Phase 21 (5.6%)

Trials by Status

completed18100%

Recent Activity

0 active trials
Showing 5 of 18
completedphase_1

Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors

NCT02857920
completedphase_1

Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors

NCT02843204
completedphase_1

Combination of Cryosurgey and NK Immunotherapy for Recurrent Laryngeal Cancer

NCT02849314
completedphase_1

Combination of Cryosurgey and NK Immunotherapy for Recurrent Ovarian Cancer

NCT02849353
completedphase_1

Combination of Cryosurgey and NK Immunotherapy for Recurrent Cervical Cancer

NCT02849340
View all 18 trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT02857920Phase 1

Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors

Completed
NCT02843204Phase 1

Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors

Completed
NCT02849314Phase 1

Combination of Cryosurgey and NK Immunotherapy for Recurrent Laryngeal Cancer

Completed
NCT02849353Phase 1

Combination of Cryosurgey and NK Immunotherapy for Recurrent Ovarian Cancer

Completed
NCT02849340Phase 1

Combination of Cryosurgey and NK Immunotherapy for Recurrent Cervical Cancer

Completed
NCT02845856Phase 1

Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer

Completed
NCT02843802Phase 1

Combination of Cryosurgery and NK Immunotherapy for Advanced Liver Cancer

Completed
NCT02843126Phase 1

Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer

Completed
NCT02843815Phase 1

Combination of Cryosurgery and NK Immunotherapy for Advanced Non-Small Cell Lung Cancer

Completed
NCT02844335Phase 1

Combination of Cryosurgery and NK Immunotherapy for Advanced Breast Cancer

Completed
NCT02849327Phase 1

Combination of Cryosurgey and NK Immunotherapy for Recurrent Pharyngeal Cancer

Completed
NCT02843581Phase 1

Combination of Cryosurgery and NK Immunotherapy for Advanced Esophageal Cancer

Completed
NCT02849379Phase 1

Combination of Cryosurgey and NK Immunotherapy for Recurrent Tongue Cancer

Completed
NCT02843061Phase 1

Combination of Rituximab and NK Immunotherapy for B Lymphoma

Completed
NCT02843607Phase 1

Combination of Cryosurgery and NK Immunotherapy for Advanced Kidney Cancer

Completed
NCT02849366Phase 1

Combination of Cryosurgery and NK Immunotherapy for Recurrent Sarcoma

Completed
NCT02853903Phase 2

Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid Tumors

Completed
NCT02849015Phase 1

Combination of Cryosurgery and NK Immunotherapy for Tumors in Transplanted Liver

Completed

All 18 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
18